Economic evaluation of SQ-standardized grass allergy immunotherapy tablet (Grazax®) in children

ClinicoEconomics and Outcomes Research

Volumn 6, Issue 1, 2014, Pages 187-196

  Ronaldson, Sarah ^a   Taylor, Matthew ^a   Bech, Peter G ^b   Shenton, Ruth ^a   Bufe, Albrecht ^c  

^a UNIVERSITY OF YORK   (United Kingdom)

^b ALK ABELLÓ   (Denmark)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Cost; Cost benefit; Cost effectiveness; Infant; Quality of life; Rhinoconjunctivitis; United Kingdom

Indexed keywords

BUDESONIDE; CROMOGLYCATE DISODIUM; FLUTICASONE; GRASS POLLEN VACCINE; LORATADINE; PREDNISOLONE; SALBUTAMOL;

ADOLESCENT; ALLERGIC ASTHMA; ARTICLE; ASTHMA; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG WITHDRAWAL; ECONOMIC EVALUATION; GRASS POLLEN; GRASS POLLEN INDUCED ALLERGIC RHINOCONJUNCTIVITIS; GRASS POLLEN INDUCED RHINOCONJUNCTIVITIS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PHLEUM PRATENSE; POLLEN ALLERGY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS; TABLET; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT;

EID: 84898712566     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S44079     Document Type: Article

References (44)

1. Bauchau V, Durham S. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004;24:758-764.
2. Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368:733-743.
3. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63 Suppl 86: 8-160.
4. Bousquet J, Van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108:S147-S334.
5. Linneberg A, Henrik Nielsen N, Frolund L, et al. The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study. Allergy. 2002;57:1048-1052.
6. Royal College of Physicians. Allergy: the unmet need. A blueprint for better patient care. A report of the Royal College of Physicians Working Party on the provision of allergy services in the UK. London, UK: Royal College of Physicians; 2003. Available from: http://www.bsaci.org/pdf/allergy_the_unmet_need.pdf. Accessed October 3, 2013.
7. Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62:943-948.
8. Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). The J Allergy Clin Immunol. 2002;109: 251-256.
9. Niggemann B, Jacobsen L, Dreborg S, et al. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy. 2006;61:855-859.
10. Bufe A, Eberle P, Franke-Beckmann E, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol. 2009;123:167-173+e7.
11. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999;341:468-475.
12. Dahl R, Kapp A, Colombo G, et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol. 2008;121: 512-518+e2.
13. Di Rienzo V, Marcucci F, Puccinelli P, et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy. 2003;33:206-210.
14. Durham SR, Yang WH, Pedersen MR, et al. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;117:802-809.
15. Durham SR, et al. Sustained efficacy of the SQ-standardized grass allergy immunotherapy tablet during the peak grass pollen season 2 years after treatment. Allergy. 2012;65:1875.
16. Bachert C, Vestenbaek U, Christensen J, et al. Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen-induced rhinoconjunctivitis - a Northern European perspective. Clin Exp Allergy. 2007;37:772-779.
17. Berto P, Passalacqua G, Crimi N, et al. Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study. Ann Allergy Asthma Immunol. 2006;97:615-621.
18. Canonica GW, Poulsen PB, Vestenbaek U. Cost-effectiveness of Grazax for prevention of grass pollen-induced rhinoconjunctivitis in Southern Europe. Respir Med. 2007;101:1885-1894.
19. Nasser S, Vestenbaek U, Beriot-Mathiot A, et al. Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma. Allergy. 2008;63:1624-1629.
20. Bufe A, Henmar H, Gronager P, et al. Grass allergen tablet immunotherapy in children induces IgG4 antibody and IgEblocking responses similar to those seen in adults. Poster presented at the XXVIII EAACI Congress of the European Academy of Allergy and Clinical Immunology, Warszawa, Poland, June 6-10, 2009.
21. ALK-Abello Ltd. Grazax: Summary of product characteristics. Hørsholm, Denmark: ALK-Abello Ltd; 2007.
22. Mosbech H, Osterballe O. Does the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollenrhinitis. Allergy. 1988;43:523-529.
23. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary 57. London, UK: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2009.
24. Curtis L. Unit Costs of Health and Social Care 2008. Kent, UK: Personal Social Services Research Unit; 2008.
25. Department of Health. NHS Reference Costs 2007/08. London, UK: Department of Health; 2008.
26. Dasgupta R, Guest JF. Factors affecting UK primary-care costs of managing patients with asthma over 5 years. Pharmacoeconomics. 2003;21:357-369.
27. NHS Quality Improvement Scotland. Asthma attack - targeting emergency asthma contacts in children. 2005. Available from: http://www.healthcareimprovementscotland.org/previous_resources/audit_report/asthma_emergency_contacts.aspx?theme=mobile. Accessed October 3, 2013.
28. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. Oxford, UK: Oxford University Press; 2005.
29. Petersen KD, Kronborg C, Gyrd-Hansen D, et al. Quality of life in rhinoconjunctivitis assessed with generic and disease-specific questionnaires. Allergy. 2008;63:284-291.
30. National Prescribing Centre. Common questions about hay fever. MeReC Bulletin. 2004;14:17-20.
31. European Federation of Allergy and Airway Diseases Patients Association. Results of the patient voice allergy survey. Impact of allergic rhinitis in Europe [Summary Report]. 2005. Available from: http://www.efanet.org/2005/06/. Accessed November 11, 2013.
32. Hanmer J, Lawrence WF, Anderson JP, et al. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making. 2006;26: 391-400.
33. Schermer TR, Thoonen BP, van den Boom G, et al. Randomized controlled economic evaluation of asthma self-management in primary health care. Am J Respir Crit Care Med. 2002;166:1062-1072.
34. HM Treasury. Appraisal and Evaluation in Central Government (The Green Book). London, UK: HM Treasury; 2003. Available from: https://www.gov.uk/government/publications/the-green-book-appraisal-andevaluation-in-central-governent. Accessed October 3, 2013.
35. National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. London, UK: National Institute for Health and Clinical Excellence; 2008.
36. Hankin CS, Cox L, Lang D, et al. Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort study. Ann Allergy Asthma Immunol. 2010;104:79-85.
37. Bruggenjurgen B, Reinhold T, Brehler R, et al. Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma. Ann Allergy Asthma Immunol. 2008;101:316-324.
38. Keiding H, Jorgensen KP. A cost-effectiveness analysis of immunotherapy with SQ allergen extract for patients with seasonal allergic rhinoconjunctivitis in selected European countries. Curr Med Res Opin. 2007;23:1113-1120.
39. Pokladnikova J, Krcmova I, Vlcek J. Economic evaluation of sublingual vs subcutaneous allergen immunotherapy. Ann Allergy Asthma Immunol. 2008;100:482-489.
40. Buxton MJ, Sullivan SD, Andersson LF, et al. Country-specific costeffectiveness of early intervention with budesonide in mild asthma. Eur Respir J. 2004;24:568-574.
41. Paltiel AD, Fuhlbrigge AL, Kitch BT, et al. Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: results from the asthma policy model. J Allergy Clin Immunol. 2001;108:39-46.
42. Rutten-van Molken MP, Van Doorslaer EK, Jansen MC, et al. Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;151:975-982.
43. Sullivan SD, Weiss KB, Lynn H, et al. The cost-effectiveness of an inner-city asthma intervention for children. J Allergy Clin Immunol. 2002;110:576-581.
44. Smith AM, Rezvani M, Bernstein JA. Is response to allergen immunotherapy a good phenotypic marker for differentiating between allergic rhinitis and mixed rhinitis? Allergy Asthma Proc. 2011;32: 49-54.